AstraZeneca says it plans to participate in the next round of Medicare negotiations under the Inflation Reduction Act. But ...

On the J&J's fourth-quarter earnings call, executives stood by Intra-Cellular’s projection that Caplyta could eclipse $5 ...

A little-known Chinese biotech startup has zipped ahead of US companies in one of the gene editing field’s most competitive ...

Samsung Biologics closed 2024 on several high notes, reaching its highest annual revenue to date — and just a week ago, ...

HHS Secretary nominee Robert F. Kennedy Jr. will divest his interests in several biopharma companies, including CRISPR ...

Quantum Health laid off 4% of workforce shortly after naming Dayne Williams as CEO. The company serves 3M+ members for ...

Xilio's vilastobart plus Roche's Tecentriq shows partial responses in colorectal cancer trial, but company faces cash ...

Just over 20 years ago, the people of California voted to spend billions of dollars on an exciting new idea to remake ...

Study links GLP-1 diabetes drugs like Novo's Ozempic and Eli Lilly's Mounjaro to 12% lower Alzheimer's risk, ahead of Novo's ...

One of Inhibrx Biosciences’ antibody candidates has shown encouraging early efficacy in colorectal cancer. But its safety is ...

A biotech developing what it says is an “opioid-like” pain reliever released Phase 3 data Wednesday morning claiming the drug ...

J&J's depression drug Spravato hits $1B in 2024 sales, up 56% from 2023, with expanded label approval and 140,000+ patients ...